Please login to the form below

Not currently logged in


This page shows the latest Vumerity news and features for those working in and with pharma, biotech and healthcare.

Biogen triumphs over Mylan’s Tecfidera patent challenge

Biogen triumphs over Mylan’s Tecfidera patent challenge

Biogen does, however, have its own next-generation MS treatment – Vumerity (diroximel fumarate) – which was recently approved for the treatment of relapsing forms of the disease. ... For comparison, while Tecfidera is a billion-dollar product,

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...